ImmunoGen

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, July 3, 2023
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, ImmunoGen, Cancer, Employment, Spacecraft, RSU, IMGN, Pharmaceutical industry

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

Key Points: 
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The options have an exercise price of $18.87 per share, which is equal to the closing price of ImmunoGen’s common stock on the Nasdaq Global Select Market on June 30, 2023.
  • Each option will vest as to 25% of the shares underlying such option on the first anniversary of the grant date and as to an additional 6.25% of the shares underlying the option quarterly thereafter, subject to each employee’s continued employment on each vesting date.
  • Each option and RSU is subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option agreement and an RSU agreement covering the respective grants.

Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial Officer

Retrieved on: 
Thursday, June 15, 2023
AACR, General Electric, Chairperson, Economics, ImmunoGen, CFO, Amherst College, Management, Meru Networks

Additionally, Greg has been designated as the Company’s principal financial officer, succeeding Bill Lundberg, M.D., in such role.

Key Points: 
  • Additionally, Greg has been designated as the Company’s principal financial officer, succeeding Bill Lundberg, M.D., in such role.
  • In connection with his appointment as the Company’s Chief Financial Officer, on June 14, 2023, Greg resigned from the Company’s Board of Directors.
  • “Greg brings industry-leading financial acumen and has been a great source of insight on the Merus Board of Directors.
  • Greg transitioned to the biotech industry after beginning his career at General Electric, where he served in increasingly senior financial roles over fourteen years.

ImmunoGen Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

Retrieved on: 
Friday, June 9, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, CRC, CCR, US Foods, Senior, European Hematology Association, CRH, DOR, Food, Cancer, Bone marrow, De novo, Associate, IMGN, MD Anderson Cancer Center, Congress, Death, HIV disease progression rates, MD, Patient, Cytokine release syndrome, CELL, University, EHA, CRi, ImmunoGen, CR, Toxic leukoencephalopathy, Mortality, Spacecraft, FDA, BPDCN, ORR, PR, Safety, Disease, Vaccine, Pharmaceutical industry, Medical device, Nursing, Leukemia

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced updated data from an interim analysis of the Phase 2 CADENZA trial of pivekimab sunirine (pivekimab) in patients with frontline and relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Key Points: 
  • ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced updated data from an interim analysis of the Phase 2 CADENZA trial of pivekimab sunirine (pivekimab) in patients with frontline and relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN).
  • The data will be presented in an oral session on Sunday, June 11 at the European Hematology Association (EHA) 2023 Congress in Frankfurt, Germany.
  • The CADENZA trial is enrolling frontline BPDCN patients, including those with de novo disease and those with a prior or concomitant hematologic malignancy (PCHM).
  • As of the May 19, 2023 data cutoff, data were available for 79 BPDCN patients (30 frontline, 49 R/R).

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, ImmunoGen, Cancer, Employment, Spacecraft, RSU

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

Key Points: 
  • The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual’s entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The options have an exercise price of $13.64 per share, which is equal to the closing price of ImmunoGen’s common stock on the Nasdaq Global Select Market on May 31, 2023.
  • Each option will vest as to 25% of the shares underlying such option on the first anniversary of the grant date and as to an additional 6.25% of the shares underlying the option quarterly thereafter, subject to such employee’s continued employment on each vesting date.
  • Each option and RSU is subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option agreement and an RSU agreement covering the respective grants.

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

Retrieved on: 
Friday, May 26, 2023
Optimism, Senior, Survival, Merck Group, Doctor of Philosophy, IMGN, GILD, MD, NUALS Arts and Literary Annual Meet, Patient, Sacituzumab govitecan, SVP, News, Business development, Brain, DPD, Hope, Mirvetuximab soravtansine, B-cell lymphoma, Gilead, Bortezomib, ONC, Randomness, TSX, Entrepreneurship, Safety, Axicabtagene ciloleucel, Gilead Sciences, Oncolytics Biotech, Neuro-Oncology (journal), CDK, Overalls, Cancer, Lung cancer, ImmunoGen, CBR, National Cancer Institute, Lymphoma, Daratumumab, ORR, Glioma, Pfizer, Progression-free survival, Paclitaxel, PVD, Dexamethasone, Fast track (FDA), ASCO, American Society of Clinical Oncology, Mantle cell lymphoma, Pelareorep, EHA, Multiple myeloma, Metastatic breast cancer, Society, Female, Breast cancer, Pharmaceutical industry, Birth control, Vaccine

VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group  -  The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there's plenty of optimism ahead for the findings and intriguing data set to be presented, with oral presentations from some of the biotech sector's finest and up-and-comers, including from Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoGen, Inc. (NASDAQ:IMGN), Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Legend Biotech Corporation (NASDAQ:LEGN), and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

Key Points: 
  • According to the National Cancer Institute, HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases.
  • It's worth noting that Oncolytics has stated that it will also be presenting updated data from May 2023 at the oral presentation.
  • Additional data will be presented during the 2023 ASCO oral presentation.
  • Bringing in eight presentations to ASCO and EHA 2023 Annual Meetings, Legend Biotech Corporation (NASDAQ:LEGN) is set to deliver new and updated data from the CARTITUDE Clinical Development Program.

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

Retrieved on: 
Friday, May 26, 2023
Optimism, Senior, Survival, Merck Group, Doctor of Philosophy, IMGN, GILD, MD, NUALS Arts and Literary Annual Meet, Patient, Sacituzumab govitecan, SVP, News, Business development, Brain, DPD, Hope, Mirvetuximab soravtansine, B-cell lymphoma, Gilead, Bortezomib, ONC, Randomness, TSX, Entrepreneurship, Safety, Axicabtagene ciloleucel, Gilead Sciences, Oncolytics Biotech, Neuro-Oncology (journal), CDK, Overalls, Cancer, Lung cancer, ImmunoGen, CBR, National Cancer Institute, Lymphoma, Daratumumab, ORR, Glioma, Pfizer, Progression-free survival, Paclitaxel, PVD, Dexamethasone, Fast track (FDA), ASCO, American Society of Clinical Oncology, Mantle cell lymphoma, Pelareorep, EHA, Multiple myeloma, Metastatic breast cancer, Society, Female, Breast cancer, Pharmaceutical industry, Birth control, Vaccine

VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group  -  The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there's plenty of optimism ahead for the findings and intriguing data set to be presented, with oral presentations from some of the biotech sector's finest and up-and-comers, including from Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoGen, Inc. (NASDAQ:IMGN), Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Legend Biotech Corporation (NASDAQ:LEGN), and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

Key Points: 
  • According to the National Cancer Institute, HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases.
  • It's worth noting that Oncolytics has stated that it will also be presenting updated data from May 2023 at the oral presentation.
  • Additional data will be presented during the 2023 ASCO oral presentation.
  • Bringing in eight presentations to ASCO and EHA 2023 Annual Meetings, Legend Biotech Corporation (NASDAQ:LEGN) is set to deliver new and updated data from the CARTITUDE Clinical Development Program.

ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Jefferies Healthcare Conference

Retrieved on: 
Wednesday, May 24, 2023
Biotechnology, Pharmaceutical, Health, Oncology, ImmunoGen, Cancer, Spacecraft, Conference, IMGN, Pharmaceutical industry, Broadcasting

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference in New York, NY.

Key Points: 
  • ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference in New York, NY.
  • The presentation is scheduled for June 7, 2023 at 9:00 am ET.
  • A webcast of the presentation will be accessible through the “Investors and Media” section of the Company’s website, www.immunogen.com .
  • Following the live webcast, a replay will be available at the same location.

PM360 Announces Winners of The Ninth Annual ELITE 100 Awards

Retrieved on: 
Tuesday, May 16, 2023
Nexium, Data science, Marketing, GoodRx, EVP, Hospira, Associate, Cardinal Health, Patient, McCourt, HR, Disease, Eli Lilly and Company, Constipation, Attention, Snow, Diagnosis, Entrepreneurship, Growth, Digital marketing, Immunology, FAAN, Engagement, Organon, Caregiver, PR, Ironwood Pharmaceuticals, Exception, COVID-19, IBS-C, Health, ELITE, Boehringer Ingelheim, Abdominal pain, Sustainability, ImmunoGen, RN, Bloating, CO, Providers, Glaucoma, Lead, Mirati Therapeutics, Regulatory science, AstraZeneca, HCP, Gastroesophageal reflux disease, Veeva Systems, Novartis, Omeprazole, Management, Pharmaceutical industry, Beauty salon, Generic drug, Esomeprazole, GERD

NEW YORK, May 16, 2023 /PRNewswire/ -- PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of its 9th Annual ELITE 100. The ELITE (Exceptional • Leaders • Innovators • Transformers • Entrepreneurs) represent the most influential people and teams in the healthcare and life sciences industries based on their career accomplishments. Out of more than 500 submissions, 100 winners are selected by the PM360 editorial staff across various categories that span every facet of the industry.

Key Points: 
  • NEW YORK, May 16, 2023 /PRNewswire/ -- PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of its 9th Annual ELITE 100.
  • Out of more than 500 submissions, 100 winners are selected by the PM360 editorial staff across various categories that span every facet of the industry.
  • PM360 also selects one person as the "Uber ELITE," or the individual among the nominees who best personifies the criteria of a PM360 ELITE.
  • McCourt will serve as the keynote speaker at the annual ELITE 100 Awards Event to celebrate this year's winners.

ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Tuesday, May 9, 2023
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Exercise, Attention, Floor, File, The 8th Floor, Telephone, Cancer, Guggenheim, ImmunoGen, IMGN, Mirvetuximab soravtansine, Sale, Public expenditure, Goldman Sachs, Prospectus, Jefferies Group, Madison Avenue, Security (finance), Spacecraft, Guggenheim Partners

The shares of common stock were sold at a price of $12.50 per share before underwriting discounts and commissions.

Key Points: 
  • The shares of common stock were sold at a price of $12.50 per share before underwriting discounts and commissions.
  • All of the shares of common stock in the offering were sold by ImmunoGen.
  • The total gross proceeds from the offering (before deducting the underwriting discounts and offering expenses) were $373.8 million.
  • Jefferies, Goldman Sachs & Co. LLC, and Guggenheim Securities acted as joint book-running managers for the offering.

ImmunoGen Announces Results from the Phase 3 MIRASOL Trial Selected as Late-Breaking Presentation for ASCO 2023 Annual Meeting

Retrieved on: 
Tuesday, May 9, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Abstract, CT, Senior, Fallopian tube cancer, Overalls, Survival, Cancer, Fallopian tube, Gynecologic Oncology (journal), Peritonitis, ImmunoGen, Mirvetuximab soravtansine, IMGN, Associate, ASCO, Bevacizumab, American Society of Clinical Oncology, MD, Patient, University, Randomness, Clinical research, University of Oklahoma, Annual general meeting, Spacecraft, GOG, Society, Safety, Birth control, Maintenance

"We are honored that MIRASOL has been selected as a late-breaker presentation at ASCO, and pleased that we will be able to share the results from the trial so quickly after they became available," said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen.

Key Points: 
  • "We are honored that MIRASOL has been selected as a late-breaker presentation at ASCO, and pleased that we will be able to share the results from the trial so quickly after they became available," said Anna Berkenblit, MD, Senior Vice President and Chief Medical Officer of ImmunoGen.
  • "Having demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to investigator's choice of single-agent chemotherapy, I believe ELAHERE has the potential to be practice changing in FRα-positive, platinum-resistant ovarian cancer."
  • Title: Phase III MIRASOL (GOG 3045/ENGOT-ov55) Study: Initial Report of Mirvetuximab Soravtansine vs.
  • ImmunoGen will present two additional trial-in-progress posters at ASCO.